Literature DB >> 12137079

Hepatitis A vaccine: is it being used to best advantage?

David W Scheifele1, Jan Ochnio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12137079      PMCID： PMC116641     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  The cost of hepatitis A infections in American adolescents and adults in 1997.

Authors:  J J Berge; D P Drennan; R J Jacobs; A Jakins; A S Meyerhoff; W Stubblefield; M Weinberg
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Control of hepatitis A through routine vaccination of children.

Authors:  F Averhoff; C N Shapiro; B P Bell; I Hyams; L Burd; A Deladisma; E P Simard; D Nalin; B Kuter; C Ward; M Lundberg; N Smith; H S Margolis
Journal:  JAMA       Date:  2001-12-19       Impact factor: 56.272

3.  National Advisory Committee on Immunization (NACI). Statement on the prevention of hepatitis A infections.

Authors: 
Journal:  Can Commun Dis Rep       Date:  1994-08-30

4.  Past infection with hepatitis A virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs.

Authors:  J J Ochnio; D Patrick; M Ho; D N Talling; S R Dobson
Journal:  CMAJ       Date:  2001-08-07       Impact factor: 8.262

5.  Current hepatitis A status in Canada.

Authors:  J Wu; S Zou; A Giulivi
Journal:  Can J Infect Dis       Date:  2001-11

Review 6.  Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Authors:  J Furesz; D W Scheifele; L Palkonyay
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

7.  The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies.

Authors:  B P Bell; C N Shapiro; M J Alter; L A Moyer; F N Judson; K Mottram; M Fleenor; P L Ryder; H S Margolis
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226
  7 in total
  3 in total

Review 1.  Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Authors:  Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  A review of interventions triggered by hepatitis A infected food-handlers in Canada.

Authors:  Andrea C Tricco; Ba' Pham; Bernard Duval; Gaston De Serres; Vladimir Gilca; Linda Vrbova; Andrea Anonychuk; Murray Krahn; David Moher
Journal:  BMC Health Serv Res       Date:  2006-12-08       Impact factor: 2.655

Review 3.  Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review.

Authors:  Ba' Pham; Bernard Duval; Gaston De Serres; Vladimir Gilca; Andrea C Tricco; Jan Ochnio; David W Scheifele
Journal:  BMC Infect Dis       Date:  2005-07-07       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.